Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".
作者信息
Goyal Manjeet Kumar
机构信息
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
出版信息
Rheumatol Ther. 2025 Apr;12(2):401-402. doi: 10.1007/s40744-024-00740-8. Epub 2025 Jan 20.
Abstract
摘要
相似文献
1
Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".致编辑的信：关于“托法替布与肿瘤坏死因子抑制剂安全性和疗效的地理差异：ORAL Surveillance事后分析”
Rheumatol Ther. 2025 Apr;12(2):401-402. doi: 10.1007/s40744-024-00740-8. Epub 2025 Jan 20.
2
A Response to: Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".对《致编辑的信：关于托法替布与肿瘤坏死因子抑制剂安全性和有效性的地理差异：ORAL Surveillance的事后分析》的回复
Rheumatol Ther. 2025 Apr;12(2):403-405. doi: 10.1007/s40744-024-00739-1. Epub 2025 Jan 20.
3
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a analysis of ORAL Surveillance.接受托法替布或肿瘤坏死因子抑制剂治疗的类风湿性关节炎患者的疾病活动度及不良事件：ORAL监测分析
Ther Adv Musculoskelet Dis. 2023 Nov 6;15:1759720X231201047. doi: 10.1177/1759720X231201047. eCollection 2023.
4
Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of the ORAL Surveillance Study.接受托法替尼或肿瘤坏死因子抑制剂治疗的拉丁美洲类风湿关节炎患者的心血管事件、恶性肿瘤和疗效结局：ORAL 监测研究的事后分析。
J Clin Rheumatol. 2024 Aug 1;30(5):208-216. doi: 10.1097/RHU.0000000000002106. Epub 2024 Jun 17.
5
Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.托法替布与肿瘤坏死因子抑制剂安全性和疗效的地理差异：ORAL Surveillance研究的事后分析
Rheumatol Ther. 2024 Oct;11(5):1217-1235. doi: 10.1007/s40744-024-00693-y. Epub 2024 Jul 26.
6
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.托法替尼与肿瘤坏死因子抑制剂治疗伴或不伴动脉粥样硬化性心血管疾病史的类风湿关节炎患者的主要不良心血管事件风险：来自 ORAL Surveillance 的事后分析。
Ann Rheum Dis. 2023 Jan;82(1):119-129. doi: 10.1136/ard-2022-222259. Epub 2022 Sep 22.
7
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.托法替布对比 TNF 抑制剂治疗类风湿关节炎患者的延长主要不良心血管事件终点的风险：一项 3b/4 期随机安全性研究的事后分析。
RMD Open. 2024 Apr 12;10(2):e003912. doi: 10.1136/rmdopen-2023-003912.
8
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.预测接受托法替尼或肿瘤坏死因子抑制剂治疗的类风湿关节炎患者静脉血栓栓塞风险的生物标志物。
RMD Open. 2022 Nov;8(2). doi: 10.1136/rmdopen-2022-002571.
9
Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry.托法替布与肿瘤坏死因子抑制剂相比的有效性，以及类风湿关节炎患者接受不同治疗线托法替布治疗的有效性：来自美国CorEvitas类风湿关节炎注册研究的结果
Clin Rheumatol. 2025 Feb;44(2):635-648. doi: 10.1007/s10067-024-07245-3. Epub 2024 Dec 20.
10
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.鉴定两种托法替布亚群与 TNF 抑制剂的相对风险不同：一项开放性标签、随机对照研究 ORAL Surveillance 的分析。
Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
本文引用的文献
1
Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.托法替布与肿瘤坏死因子抑制剂安全性和疗效的地理差异：ORAL Surveillance研究的事后分析
Rheumatol Ther. 2024 Oct;11(5):1217-1235. doi: 10.1007/s40744-024-00693-y. Epub 2024 Jul 26.
Zotero 插件